2023 Fiscal Year Final Research Report
The clinical applications of long non-coding RNA and extracellular vesicles to diagnosis and therapy for pancreatic cancer
| Project/Area Number |
21K07954
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
水上 裕輔 旭川医科大学, 医学部, 教授 (30400089)
小野 裕介 医療法人徳洲会札幌東徳洲会病院医学研究所, ゲノム診断研究部, 部門長 (40742648)
小暮 高之 東北医科薬科大学, 医学部, 准教授 (70400330)
藤井 聡 北海道大学, 大学病院, 臨床検査管理医師 (90291228)
谷上 賢瑞 東京大学, アイソトープ総合センター, 特任准教授 (90648627)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 膵癌 / ncRNA / lncRNA / 細胞外小胞 / リキッドバイオプシー |
|---|
| Outline of Final Research Achievements |
There is a strong need for reliable biomarkers for early diagnosis for pancreatic ductal adenocarcinoma (PDAC). Some RNAs are carried within extracellular vesicles (EVs), and EV-encapsulated RNAs in blood have been utilized as a biomarker. We identified highly expressed lncRNAs (LINC02280, HEVEPA) in EVs derived from patients with PDAC. In vitro and vivo studies, LINC02280 could promote tumor cell invasion and migration through induction of epithelial-mesenchymal transition (EMT) pathway whereas HEVEPA could inhibit apoptosis in PDAC cells. In serum EVs, the expression levels of LINC02280 and HEVEPA were highly expressed in PDAC patients compared to healthy individuals and intraductal papillary mucinous neoplasms (IPMNs) patients. A combination of EV lncRNAs showed good performance in predicting PDAC diagnosis. Detecting those candidate RNAs and establishing EV RNA panel would have a potential to improve the diagnostic accuracy for early stage of PDAC.
|
| Free Research Field |
消化器内科学分野
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、膵癌患者血清EV中に発現する新規のlncRNAを同定した。現状では早期診断に有用なマーカーのない膵癌において、これらのRNAは新たな診断標的として、さらには治療標的としての有用性が期待される。今後は、血液中のRNA発現とDNA変異解析を併用し、さらなる膵癌診断能の向上を図り、膵癌診断パネルとしての臨床実装化を目指す。
|
